PortalPublikationenEmergence of linezolid-resistance in vancomycin-resistant En...

Emergence of linezolid-resistance in vancomycin-resistant Enterococcus faecium ST117 associated with increased linezolid-consumption

Standard

Emergence of linezolid-resistance in vancomycin-resistant Enterococcus faecium ST117 associated with increased linezolid-consumption. / Olearo, Flaminia; Both, Anna; Belmar Campos, Cristina; Hilgarth, Heike; Klupp, Eva-Maria; Hansen, Jan Lennart; Maurer, Florian P; Christner, Martin; Aepfelbacher, Martin; Rohde, Holger.

in: INT J MED MICROBIOL, Jahrgang 311, Nr. 2, 151477, 02.2021.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Olearo, F, Both, A, Belmar Campos, C, Hilgarth, H, Klupp, E-M, Hansen, JL, Maurer, FP, Christner, M, Aepfelbacher, M & Rohde, H 2021, 'Emergence of linezolid-resistance in vancomycin-resistant Enterococcus faecium ST117 associated with increased linezolid-consumption', INT J MED MICROBIOL, Jg. 311, Nr. 2, 151477. https://doi.org/10.1016/j.ijmm.2021.151477

APA

Olearo, F., Both, A., Belmar Campos, C., Hilgarth, H., Klupp, E-M., Hansen, J. L., Maurer, F. P., Christner, M., Aepfelbacher, M., & Rohde, H. (2021). Emergence of linezolid-resistance in vancomycin-resistant Enterococcus faecium ST117 associated with increased linezolid-consumption. INT J MED MICROBIOL, 311(2), [151477]. https://doi.org/10.1016/j.ijmm.2021.151477

Vancouver

Olearo F, Both A, Belmar Campos C, Hilgarth H, Klupp E-M, Hansen JL et al. Emergence of linezolid-resistance in vancomycin-resistant Enterococcus faecium ST117 associated with increased linezolid-consumption. INT J MED MICROBIOL. 2021 Feb;311(2). 151477. https://doi.org/10.1016/j.ijmm.2021.151477

Bibtex

@article{6be40025ce63451ab3c5ea2cad063b9b,
title = "Emergence of linezolid-resistance in vancomycin-resistant Enterococcus faecium ST117 associated with increased linezolid-consumption",
abstract = "OBJECTIVE: We aim to describe the epidemiological, clinical and microbiological characteristics of the linezolid- and vancomycin- resistant Enterococcus faecium (LVRE) in a tertiary care hospital in Germany.METHODS: We conducted a retrospective analysis of 196 LVRE cases observed from 1st January 2012 to 31th December 2018. Patients' medical charts were reviewed and available LVRE (n = 102) were subjected to whole-genome-sequencing. Antibiotic consumption was measured in defined daily dose (DDD)/100 bed-days (BD).RESULTS: The prevalence of LVRE isolates among VRE was 6.3 % in 2018. Most patients had an onco-hematological disease (134/196, 68.4 %). From 2012-2018 an increase of +356.7 % of linezolid defined daily dose/100 bed-days was observed. In 71.4 % (90/126, 70 missing values) of the patients, linezolid was prescribed in the previous 6 months. The median exposure to linezolid was 15 days (Interquartile, IQR 9-23). 42/196 (21.4 %) patients had an LVRE-related infection with an overall 30-day mortality rate of 33 %. In 121/196 (61.7 %) patients, linezolid-susceptible VREfm were isolated before LVRE, suggesting secondary acquisition of linezolid resistance. Genetic analysis revealed that most isolates belonged to ST117 (64/102 available isolates, 62.7 %). The G2576T 23S rDNA mutation was identified as the most common resistance mechanism (96/102, 94.1 %). poxtA was identified in two isolates, while cfr, and optrA were not detected.CONCLUSIONS: Incidence of LVRE related to 23S rDNA mutations is rising and probably associated with antibiotic consumption. Restrictions in the use of linezolid may be needed in order to retain therapeutic options in VRE.",
author = "Flaminia Olearo and Anna Both and {Belmar Campos}, Cristina and Heike Hilgarth and Eva-Maria Klupp and Hansen, {Jan Lennart} and Maurer, {Florian P} and Martin Christner and Martin Aepfelbacher and Holger Rohde",
note = "Copyright {\textcopyright} 2021. Published by Elsevier GmbH.",
year = "2021",
month = feb,
doi = "10.1016/j.ijmm.2021.151477",
language = "English",
volume = "311",
journal = "INT J MED MICROBIOL",
issn = "1438-4221",
publisher = "Urban und Fischer Verlag GmbH und Co. KG",
number = "2",

}

RIS

TY - JOUR

T1 - Emergence of linezolid-resistance in vancomycin-resistant Enterococcus faecium ST117 associated with increased linezolid-consumption

AU - Olearo, Flaminia

AU - Both, Anna

AU - Belmar Campos, Cristina

AU - Hilgarth, Heike

AU - Klupp, Eva-Maria

AU - Hansen, Jan Lennart

AU - Maurer, Florian P

AU - Christner, Martin

AU - Aepfelbacher, Martin

AU - Rohde, Holger

N1 - Copyright © 2021. Published by Elsevier GmbH.

PY - 2021/2

Y1 - 2021/2

N2 - OBJECTIVE: We aim to describe the epidemiological, clinical and microbiological characteristics of the linezolid- and vancomycin- resistant Enterococcus faecium (LVRE) in a tertiary care hospital in Germany.METHODS: We conducted a retrospective analysis of 196 LVRE cases observed from 1st January 2012 to 31th December 2018. Patients' medical charts were reviewed and available LVRE (n = 102) were subjected to whole-genome-sequencing. Antibiotic consumption was measured in defined daily dose (DDD)/100 bed-days (BD).RESULTS: The prevalence of LVRE isolates among VRE was 6.3 % in 2018. Most patients had an onco-hematological disease (134/196, 68.4 %). From 2012-2018 an increase of +356.7 % of linezolid defined daily dose/100 bed-days was observed. In 71.4 % (90/126, 70 missing values) of the patients, linezolid was prescribed in the previous 6 months. The median exposure to linezolid was 15 days (Interquartile, IQR 9-23). 42/196 (21.4 %) patients had an LVRE-related infection with an overall 30-day mortality rate of 33 %. In 121/196 (61.7 %) patients, linezolid-susceptible VREfm were isolated before LVRE, suggesting secondary acquisition of linezolid resistance. Genetic analysis revealed that most isolates belonged to ST117 (64/102 available isolates, 62.7 %). The G2576T 23S rDNA mutation was identified as the most common resistance mechanism (96/102, 94.1 %). poxtA was identified in two isolates, while cfr, and optrA were not detected.CONCLUSIONS: Incidence of LVRE related to 23S rDNA mutations is rising and probably associated with antibiotic consumption. Restrictions in the use of linezolid may be needed in order to retain therapeutic options in VRE.

AB - OBJECTIVE: We aim to describe the epidemiological, clinical and microbiological characteristics of the linezolid- and vancomycin- resistant Enterococcus faecium (LVRE) in a tertiary care hospital in Germany.METHODS: We conducted a retrospective analysis of 196 LVRE cases observed from 1st January 2012 to 31th December 2018. Patients' medical charts were reviewed and available LVRE (n = 102) were subjected to whole-genome-sequencing. Antibiotic consumption was measured in defined daily dose (DDD)/100 bed-days (BD).RESULTS: The prevalence of LVRE isolates among VRE was 6.3 % in 2018. Most patients had an onco-hematological disease (134/196, 68.4 %). From 2012-2018 an increase of +356.7 % of linezolid defined daily dose/100 bed-days was observed. In 71.4 % (90/126, 70 missing values) of the patients, linezolid was prescribed in the previous 6 months. The median exposure to linezolid was 15 days (Interquartile, IQR 9-23). 42/196 (21.4 %) patients had an LVRE-related infection with an overall 30-day mortality rate of 33 %. In 121/196 (61.7 %) patients, linezolid-susceptible VREfm were isolated before LVRE, suggesting secondary acquisition of linezolid resistance. Genetic analysis revealed that most isolates belonged to ST117 (64/102 available isolates, 62.7 %). The G2576T 23S rDNA mutation was identified as the most common resistance mechanism (96/102, 94.1 %). poxtA was identified in two isolates, while cfr, and optrA were not detected.CONCLUSIONS: Incidence of LVRE related to 23S rDNA mutations is rising and probably associated with antibiotic consumption. Restrictions in the use of linezolid may be needed in order to retain therapeutic options in VRE.

U2 - 10.1016/j.ijmm.2021.151477

DO - 10.1016/j.ijmm.2021.151477

M3 - SCORING: Journal article

C2 - 33524636

VL - 311

JO - INT J MED MICROBIOL

JF - INT J MED MICROBIOL

SN - 1438-4221

IS - 2

M1 - 151477

ER -